Liverpool platform will support nanomedicine developers

  27 May 2021

A new platform to support companies that are developing cutting-edge treatments for infectious diseases has been established at the University of Liverpool.

A new agreement will see The Nanotherapeutics Hub, part of Liverpool’s Centre of Excellence for Long-acting Therapeutics (CELT), work with the Infection Innovation Consortium (iiCON) to support the development of nanomedicines.

Nanomedicine is the application of nanomaterials, or nanoparticles, to medicine. Nanoparticles are a form of delivery for drugs that can reach places drugs normally couldn’t reach otherwise. It is a market projected to be worth more than £150bn by 2026.

Led by the Liverpool School of Tropical Medicine (LSTM) and backed by UKRI’s Strength in Places Fund (SIPF), iiCON is revitalising the UK’s infectious diseases product pipeline.

Further reading: Liverpool Business News
Author(s): Liverpool Business News
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed